Take the pledge to vote

For a better tommorow#AajSawaroApnaKal
  • I agree to receive emails from News18

  • I promise to vote in this year's elections no matter what the odds are.
  • Please check above checkbox.

    SUBMIT

Thank you for
taking the pledge

Vote responsibly as each vote counts
and makes a diffrence

Disclaimer:

Issued in public interest by HDFC Life. HDFC Life Insurance Company Limited (Formerly HDFC Standard Life Insurance Company Limited) (“HDFC Life”). CIN: L65110MH2000PLC128245, IRDAI Reg. No. 101 . The name/letters "HDFC" in the name/logo of the company belongs to Housing Development Finance Corporation Limited ("HDFC Limited") and is used by HDFC Life under an agreement entered into with HDFC Limited. ARN EU/04/19/13618
LIVE TV DownloadNews18 App
News18 English
News18 » Business
2-min read

US FDA Accuses India's Strides Pharma Science of Shredding, Dumping Key Documents

The investigator observed multiple bags of manufacturing documents awaiting shredding and a blue binder including the records of batches of drugs produced for the US market in a 55-gallon drum in the scrapyard.

Reuters

Updated:July 17, 2019, 5:40 PM IST
facebookTwitterskypewhatsapp
US FDA Accuses India's Strides Pharma Science of Shredding, Dumping Key Documents
Image for representation.
Loading...

Bengaluru: A US Food and Drug Administration (FDA) investigator discovered that India's Strides Pharma Science Ltd, which exports to the US market, was shredding drug production, quality and laboratory documents and dumping others in a scrapyard.

The "uncontrolled destruction" of manufacturing records and the lack of adequate documentation handling at the drugmaker's factory at Puducherry, called into question the effectiveness of its quality unit and the integrity and accuracy of its records, the regulator said in a warning letter made public on Tuesday.

The investigator observed multiple bags of manufacturing documents awaiting shredding and a blue binder including the records of batches of drugs produced for the US market in a 55-gallon drum in the scrapyard, Francis Godwin, director of the FDA's Office of Manufacturing Quality, said in the letter dated July 1.

The potential importance of individual documents wasn't made clear by the FDA.

Strides, which also has factories in Italy, Kenya and Singapore, produces drugs that treat AIDS, malaria and hepatitis. Its revenue grew 6% in the last fiscal year.

In the letter to Strides, the FDA didn't explain whether its inspectors often check scrap yards or shredding rooms for documents, or whether it was acting on some kind of tipoff to do so at the Strides plant.

In its initial response to the FDA's findings, Strides said the discarding of the binder was inadvertent.

The FDA said Strides response was "inadequate" because it did not assess how poor documentation practices affected distributed drug product or how the manufacturer would strengthen its quality unit's oversight.

The agency said it found "significant violations" of current good manufacturing practice (CGMP) regulations at the facility.

Shares of the Bengaluru-based company, which fell as much as 8% to a near one-year low earlier on Wednesday, pared some losses to end 3.4% lower.

Last month, Aurobindo Pharma Ltd was warned https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/aurobindo-pharma-limited-577033-06202019 by the FDA for ignoring impurities in an active ingredient it produced. The Hyderabad-based drugmaker recalled contaminated valsartan in January and in March.

"CGMP documents in the binder were dated as recently as January 21, 2019: seven days before our inspection. Your quality unit did not review or check these documents prior to disposal," Godwin said in the letter, addressed to Strides Chief Executive Officer Arun Kumar.

On July 2, Strides shares slumped after it said it received a warning letter from the U.S. FDA, it did not disclose the content of the letter at that time.

A Strides spokesman said on Wednesday the company did not have any further comment.

Strides bought a unit of Vivimed Labs Ltd in January. Vivimed manufactures losartan, a drug that is part of a wider recall in the United States.

The FDA's warning letter comes months after several Indian drugmakers, including Sun Pharmaceutical Ltd and Dr.Reddy's Laboratories Ltd, were named in a U.S. lawsuit against Israeli drugmaker Teva Pharmaceutical Industries Ltd accusing it of conspiring to inflate drug prices and stifle competition for generic drugs.

Get the best of News18 delivered to your inbox - subscribe to News18 Daybreak. Follow News18.com on Twitter, Instagram, Facebook, TikTok and on YouTube, and stay in the know with what's happening in the world around you – in real time.

Subscribe to Moneycontrol Pro and gain access to curated markets data, trading recommendations, equity analysis, investment ideas, insights from market gurus and much more. Get Moneycontrol PRO for 1 year at price of 3 months. Use code FREEDOM.

Read full article
Loading...
Next Story
Next Story

Also Watch

facebookTwitterskypewhatsapp
Most Active
Company Price Change %Gain
Yes Bank 56.30 -13.91
LIC Housing Fin 414.00 -10.66
Indiabulls Hsg 450.55 -6.82
DLF 144.45 -15.82
Maruti Suzuki 6,208.55 -0.33
Company Price Change %Gain
LIC Housing Fin 412.85 -10.97
Yes Bank 56.30 -13.91
DLF 144.30 -15.91
Indiabulls Hsg 449.90 -6.82
Tata Steel 333.35 -2.83
Top Gainers
Company Price Change %Gain
Britannia 2,440.75 2.36
Dr Reddys Labs 2,545.40 1.69
Tech Mahindra 682.75 1.48
TCS 2,216.00 1.36
HUL 1,872.10 1.19
Company Price Change %Gain
TCS 2,214.90 1.33
HUL 1,872.25 1.21
HCL Tech 1,078.45 0.63
Top Losers
Company Price Change %Gain
Yes Bank 56.30 -13.91
Vedanta 129.05 -7.79
Indiabulls Hsg 450.55 -6.82
Bajaj Finserv 6,767.35 -5.30
Bajaj Finance 3,114.10 -4.52
Company Price Change %Gain
Yes Bank 56.30 -13.91
Vedanta 129.05 -7.76
Bajaj Finance 3,117.80 -4.39
Coal India 180.70 -4.26
Tata Motors 107.65 -4.14

Live TV

Loading...
Countdown To Elections Results
  • 01 d
  • 12 h
  • 38 m
  • 09 s
To Assembly Elections 2018 Results